---
figid: PMC9501361__metabolites-12-00826-g004
pmcid: PMC9501361
image_filename: metabolites-12-00826-g004.jpg
figure_link: /pmc/articles/PMC9501361/figure/metabolites-12-00826-f004/
number: Figure 4
figure_title: ''
caption: 'Schematic diagram of oxylipins and associated clinical outcomes. Highlights
  of the major oxidation pathways for linoleic acid (LA), eicosapentaenoic acid (EPA),
  and docosahexaenoic acid (DHA) that include cytochrome P450 (P450 pathway)-soluble
  epoxide hydrolase (sEH), and lipoxygenase (LOX pathway) that are associated with
  clinical outcomes associated with ADRD and ADRD risk listed in . First author and
  references included for clinical outcomes: Diabetic Retinopathy, Zhao et al. [],
  Hu et al. []; Alzheimer’s Disease, Borkowski et al. []; Brain MRI Ischemic Markers
  (White Matter Hyperintensity), Yu et al. [], Shinto et al. []; Heart Disease, Zhang
  et al. [], Kim-Campbell et al. []; Ischemic stroke, Szczuko et al. []; Inflammation,
  Vasoactivity, Kim-Campbell et al. []; Atherosclerosis, Kuhn et al. [], Waddington
  et al. [], Shibata et al. []; Blood Pressure, Caligiuri et al. []; Cognition, Yu
  et al. [], Shinto et al. [], Borkowski et al. [].'
article_title: 'A Review of Oxylipins in Alzheimer’s Disease and Related Dementias
  (ADRD): Potential Therapeutic Targets for the Modulation of Vascular Tone and Inflammation.'
citation: Lynne H. Shinto, et al. Metabolites. 2022 Sep;12(9):826.
year: '2022'

doi: 10.3390/metabo12090826
journal_title: Metabolites
journal_nlm_ta: Metabolites
publisher_name: MDPI

keywords:
- review
- oxylipin
- fatty acids
- vascular dementia
- Alzheimer’s disease

---
